As we observed a general trend of downregulation of endogenous LATS1 in response to targeted therapies in HCC (Figs. 1a and 2c, and Supplementary Fig. 3e, f), we further investigated potential degradation pathways of LATS1 under these stresses. This evidence concerns the gene LATS1 and hepatocellular carcinoma.